Durvalumab (7) – Imfinzi®

Adult female patients with primary advanced endometrial cancer (stage III or IV) or recurrent endometrial cancer with mismatch repair deficiency (dMMR), who, for the treatment of − the primary advanced disease, have not yet received any systemic therapy as post-operative or adjuvant therapy, − the recurrence, have not yet received any chemotherapy

• The additional benefit is not proven.
• The results presented from the DUO-E trial are not suitable for assessing additional benefit, as the appropriate comparator therapy specified by the G-BA (dostarlimab in combination with carboplatin and paclitaxel followed by dostarlimab as monotherapy) has not been implemented in the comparative therapy used in the DUO-E study.

Courtesy translation only, please refer to the German original.